Incyte Corporation (INCY)’s Financial Results Comparing With Zealand Pharma A/S (NASDAQ:ZEAL)

As Biotechnology companies, Incyte Corporation (NASDAQ:INCY) and Zealand Pharma A/S (NASDAQ:ZEAL) are our subject to compare. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incyte Corporation 82 8.84 N/A 1.17 72.58
Zealand Pharma A/S 20 0.00 N/A 3.00 7.54

Table 1 demonstrates Incyte Corporation and Zealand Pharma A/S’s top-line revenue, earnings per share (EPS) and valuation. Zealand Pharma A/S is observed to has lower revenue, but higher earnings than Incyte Corporation. The company that is more expensive between the two has a higher P/E ratio. Incyte Corporation’s presently higher P/E ratio makes it the more expensive of the two businesses.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Incyte Corporation 0.00% 13.4% 9.8%
Zealand Pharma A/S 0.00% 0% 0%

Analyst Ratings

In next table is delivered Incyte Corporation and Zealand Pharma A/S’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Incyte Corporation 0 4 3 2.43
Zealand Pharma A/S 0 0 1 3.00

Incyte Corporation’s upside potential currently stands at 17.23% and an $92 average target price. On the other hand, Zealand Pharma A/S’s potential upside is 27.99% and its average target price is $30. The information presented earlier suggests that Zealand Pharma A/S looks more robust than Incyte Corporation as far as analyst opinion.

Insider & Institutional Ownership

The shares of both Incyte Corporation and Zealand Pharma A/S are owned by institutional investors at 94.7% and 9% respectively. 0.5% are Incyte Corporation’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Incyte Corporation 7.29% -0.59% 7.62% 6.18% 23.83% 33.54%
Zealand Pharma A/S -1.05% 3.57% 8.69% 53.95% 52.19% 94.92%

For the past year Incyte Corporation’s stock price has smaller growth than Zealand Pharma A/S.

Summary

On 8 of the 12 factors Incyte Corporation beats Zealand Pharma A/S.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companyÂ’s clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.